TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF

TAKEDA PHARMACEUTICAL CO LTD

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026

$19.61−0.06 (-0.31%)

Close on Oct 19, 2026

TAKEDA PHARMACEUTICAL CO LTD balance sheet

Annual Quarterly

JPY USD

Millions of USD, except per-share data. Shares in millions.

Line item	Q4 2026 2026-03-31	Q4 2025 2025-03-31	Q4 2024 2024-03-31	Q4 2023 2023-03-31	Q4 2022 2022-03-31	Q4 2021 2021-03-31	Q4 2020 2020-03-31	Q4 2019 2019-03-31	Q4 2018 2018-03-31	Q4 2017 2017-03-31	Q4 2016 2016-03-31
Cash & Equivalents	3,741	2,569	3,027	4,019	6,997	8,735	5,930	6,343	2,773	2,867	4,016
Cash & Short-Term Investments	3,741	2,569	3,027	4,019	6,997	8,735	5,930	6,343	2,773	2,867	4,016
Receivables	5,307	4,733	4,420	4,892	5,737	7,080	7,040	6,703	3,957	–	–
Inventory	8,779	8,121	8,001	7,431	7,025	6,816	7,064	8,309	2,005	–	–
Other Current Assets	1,022	1,065	1,117	1,212	1,162	1,110	1,062	991	545	–	–
Total Current Assets	19,427	16,819	16,920	18,064	21,357	24,527	22,965	27,042	10,158	–	–
Property, Plant & Equipment	–	–	–	12,740	13,034	13,145	12,893	12,034	5,055	–	–
Operating Lease Right-of-Use Assets	3,037	3,212	3,527	3,091	3,359	3,497	3,227	–	–	–	–
Goodwill	36,516	35,520	35,776	36,088	36,296	36,470	37,315	38,311	9,692	–	–
Intangible Assets	21,495	24,227	28,268	32,163	31,444	35,341	38,793	42,927	9,551	–	–
Deferred Tax Assets	3,434	2,473	2,605	2,757	2,985	3,198	2,865	804	612	–	–
Other Long-Term Assets	484	469	339	477	680	907	966	790	734	–	–
Total Assets	97,508	95,052	99,913	105,143	108,515	116,737	119,233	124,618	38,667	–	–
Accounts Payable	3,089	3,172	3,621	4,891	4,251	3,109	2,965	2,958	2,262	–	–
Current Debt	3,219	3,662	2,429	2,558	1,680	200	5,457	8,899	0.17	–	–
Current Income Taxes Payable	615	891	727	1,750	1,654	1,313	1,699	1,362	637	–	–
Other Current Liabilities	3,710	3,978	4,095	4,269	4,817	4,906	4,644	3,967	2,485	–	–
Total Current Liabilities	17,803	16,721	15,296	18,696	17,669	16,031	20,235	23,067	6,945	–	–
Long-Term Debt	27,468	26,460	29,603	30,454	34,103	41,707	41,909	43,061	9,281	–	–
Operating Lease Liabilities	3,737	3,825	4,098	3,611	3,831	3,946	3,436	0	–	–	–
Deferred Tax Liabilities	168	235	752	2,039	3,718	4,908	6,604	6,518	854	–	–
Other Long-Term Liabilities	627	553	535	493	553	514	491	668	643	–	–
Total Liabilities	50,797	48,782	51,811	57,274	61,714	69,931	75,268	77,763	19,671	–	–
Total Debt	30,688	30,122	32,031	33,012	35,782	41,907	47,366	51,960	9,281	–	–
Common Stock	10,657	11,305	11,087	12,628	13,803	15,081	15,513	14,850	734	–	–
Additional Paid-In Capital	11,166	11,846	11,555	13,023	14,072	15,265	15,626	14,910	854	–	–
Retained Earnings	4,478	7,923	9,200	11,609	12,185	13,651	12,740	14,415	14,664	–	–
Treasury Stock	-309	-499	-339	-756	-955	-538	-813	-516	-700	–	–
Shareholders' Equity	46,703	46,265	48,097	47,865	46,797	46,768	43,927	46,820	18,808	–	–
Noncontrolling Interest	7.59	5.97	4.90	4.14	4.15	37	37	36	188	–	–
Total Equity	46,710	46,271	48,102	47,869	46,819	46,806	43,964	46,856	18,996	17,494	17,890
Total Liabilities & Equity	97,508	95,052	99,913	105,143	108,515	116,737	119,233	124,618	38,667	–	–
Shares Outstanding(shares)	1,591	1,591	1,582	1,582	1,582	1,576	1,576	1,565	795	791	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 65.1%
Operating margin: 0.1%
Net margin: -3.4%
Return on equity, FY2026: -2.1%

Financial strength

Current ratio: 1.09
Debt to equity: 0.66
Debt to assets: 31.5%
Cash to current liabilities: 21.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.